Short answer
ImmunityBio, Inc. (IBRX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $32M (up 425.1% year over year) with net income of −$67M.
Q3 2025 key financials · XBRL
- Revenue
- $32M
- +425.1% YoY · +21.3% QoQ
- Net income
- −$67M
- +21.6% YoY · +27.3% QoQ
- Operating margin
- -173.5%
- EPS (diluted)
- −$0.06
- +53.8% YoY · +45.5% QoQ
Source: XBRL data from the ImmunityBio, Inc. (IBRX) Q3 2025 10-Q on SEC EDGAR. USD.
ImmunityBio, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: FDA approval of ANKTIVA in April 2024; commercial sales commenced but revenue timing and sufficiency remain uncertain
- Material update: Revenue Interest Payment Agreement (RIPA) restricts operations, affects cash flow, and may impede capital raising flexibility
- Regulatory risk: Ongoing FDA and MHRA regulatory compliance for ANKTIVA and other candidates involve significant expense and risk of penalties
- Operational risk: Dependence on single FDA-approved BCG strain (TICE BCG) creates supply chain vulnerability impacting ANKTIVA commercialization
- Financial risk: Cash and equivalents $257.8M vs $505M related-party convertible promissory note; need for additional financing critical to sustain operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ImmunityBio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.